294 research outputs found
Arterial Hypertension
No full textRecent progresses in the field of anticancer therapy have dramatically reduced the morbidity and mortality from many forms of malignacy. Arterial hypertension is the most common cardiovascular comorbidity encountered in oncologic patients, and according to some studies, it may be a potential risk factor for specific cancer types. Cancer patients affected by hypertension are at higher risk for the development of cardiac adverse events after specific antineoplastic treatments, specifically anthracyclines. Moreover, new-onset hypertension has emerged as an adverse event for several cancer therapies, in particular for the newer anti-vascular endothelial growth factor agents. A fundamental issue with cancer patients is therefore that hypertension must be carefully diagnosed and treated in order to prevent both early and late cardiotoxic effects of anticancer agents. At the same time, achieving optimal target values of blood pressure during anticancer treatment must be adaptable to changing status of the patient being treated for cancer
Arterial hypertension in cancer: The elephant in the room
No full textThe great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, various analyses have shown a direct relationship between hypertension and cancer incidence and mortality. Finally, many antineoplastic treatments may cause a rise in blood pressure (BP) values, particularly the novel anti VEGF agents, this possibly compromising efficacy of chemotherapy. Aim of this review is to revise the topic and the many aspects linking arterial hypertension and cancer, and to provide a comprehensive and practical guide of the current treatment approaches
The Memories of Our Future: The Memories of Maūi
No full textThis thesis proposes a way to re-inhabit and transform the adverse identity of an old offshore oil and gas platform. Located 35 kilometers off the West Coast of Taranaki, New Zealand, the Māui A Platform (also known as MPA) is transformed in this thesis design investigation into an Environmental Centre, a living retreat for ‘children’ (in fact, for adults who will be encouraged in the design to see life through the eyes of children). The intention is to generate knowledge and awareness about the environment.
The Māui A and Māui B offshore oil and gas platforms are nearing the end of their economic lifespan. Globally, the current most common decommissioning method of oil platforms involves the use of explosives at the base of the jacket. The structure is then towed to shore and dismantled. The explosives leave scars not only on the landscape the platforms once inhabited; they critically damage the surrounding marine ecology, vast numbers of marine species. This is of severe concern for the marine life and ecosystems surrounding the Māui A & Māui B Platforms as they are located in an extremely sensitive marine area where over 30 percent of the world’s cetacean species inhabit or through which they frequently migrate. Only two of these marine mammal species are not listed as ‘species of concern’ in the New Zealand Threat Classification list.
The future of these platforms does not need to cause more adversity to the environment, but rather can regenerate it. By re-purposing rather than exploding and dismantling these structures, this thesis aims to propose a way to re-inhabit the Māui A Platform and transform it into an educational retreat that enables further awareness, reconciliation, restoration, and protection of marine systems, environment, and threatened marine species. This thesis explores opportunities to create a closed circuit system as a means of providing food, fresh water, water treatment and energy for the platform.
To achieve this regenerative solution in ways that will resonate with those who visit the Māui A Platform, this project enters the realm of the imagination. The imagination is fundamental to learning - hence the proposition that this design be framed as both mythological and experiential. Narrative design – story telling – is explored as a tool to connect sustainable awareness and consciousness as a means to help educate the beneficiaries of this world – our ‘children’. To encourage the adult visitors to fully recognise that the beneficiaries are indeed our children, the thesis investigation will design the new Environmental Centre through the eyes of the child. As a tool to enhance the historic narrative of the site and context, the design strategically frames traces of important or unnoticed elements or equipment of the Māui A Platform.
In order to be understood and engaged with by ‘children’, this project enters the realm of the imagination enabling the design to be both mythological and experiential
Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (European Heart Journal - Cardiovascular Imaging (2022) 23:3 (e333–e465) DOI: 10.1093/ehjci/jeac106)
No full textThis is an erratum to: Alexander R Lyon, Teresa López-Fernández, Liam S Couch, Riccardo Asteggiano, Marianne C Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J Cutter, Evandro de Azambuja, Rudolf A de Boer, Susan F Dent, Dimitrios Farmakis, Sofie A Gevaert, Diana A Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S Salinger, Richard Stephens, Thomas M Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G Tocchetti, Peter van der Meer, Helena J H van der Pal, ESC Scientific Document Group, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC), European Heart Journal - Cardiovascular Imaging, Volume 23, Issue 10, October 2022, Pages e333–e465, https://doi.org/10.1093/ehjci/jeac106 The following change has been made to the article: In Figure 7, the category ‘Very high risk’ has been corrected online to ‘High and very high risk’
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C ardio‐ O ncology S tudy G roup of the H eart F ailure A ssociation of the E uropean S ociety of C ardiology in collaboration with the I nternational C ardio‐ O ncology S ociety
No full textRegEl Database: text-mined regulatory elements from the literature and their associations to genes and disease
No full text@article{garda2022regel,
title={RegEl corpus: identifying DNA regulatory elements in the scientific literature},
author={Garda, Samuele and Lenihan-Geels, Freyda and Proft, Sebastian and Hochmuth, Stefanie and Sch{\"u}lke, Markus and Seelow, Dominik and Leser, Ulf},
journal={Database},
volume={2022},
year={2022},
publisher={Oxford Academic}
}
# RegEl PubMed Database
This database contains the annotations generated by running [HunFlair](https://github.com/flairNLP/flair/blob/master/resources/docs/HUNFLAIR.md) models trained on the [RegEl corpus](https://zenodo.org/record/5776679) over >20M PubMed abstracts.
By pairing these annotations with the one provided by PubTator this generates a large text mining database of regulatory elements associated with genes (normalized to NCBI Gene ids) and disease (normalized to either MeSH or OMIM).
The tables composing the database are:
* abstracts.db:
- pmid = PubMed ID of the given abstracts
- sid = sentence ID of the given abstracts (from 0 to # of sentences)
- text = text of the given sentence
* gene.db and disease.db:
- pmid = PubMed ID of the given abstracts
- sid = sentence ID of the given abstracts (from 0 to # of sentences)
- etype = entity type (enhancer, promoter, TFBS)
- ann_text = mention of the regulatory element as found in the abstract
- start = position (# character) in which the mention begins
- end = position (# characters) in which the mention ends
- score = model's confidence
- cui = gene or disease identifier
- cui_symbol = official symbol of cui (if available
Association of Breast Cancer Irradiation With Cardiac Toxic Effects : A Narrative Review
No full textIMPORTANCE To promptly recognize and manage cardiovascular (CV) risk factors before, during, and after cancer treatment, decreasing the risk of cancer therapy-related cardiac dysfunction is crucial. After recent advances in breast cancer treatment, mortality rates from cancer have decreased, and the prevalence of survivors with a potentially higher CV disease risk has increased. Cardiovascular risks might be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT).OBSERVATIONS The heart disease risk seems to be higher in patients with tumors in the left breast, when other classic CV risk factors are present, and when adjunctive anthracycline-based chemotherapy is administered, suggesting a synergistic association. Respiratory control as well as modern RT techniques and their possible further refinement may decrease the prevalence and severity of radiation-induced heart disease. Several pharmacological cardioprevention strategies for decreasing cardiac toxic effects have been identified in several guidelines. However, further research is needed to ascertain the feasibility of these strategies in routine practice.CONCLUSIONS AND RELEVANCE This review found that evidence-based recommendations are lacking on the modalities for and intensity of heart disease screening, surveillance of patients after RT, and treatment of these patients. A multidisciplinary and multimodal approach is crucial to guide optimal management
- …
